BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1048 related articles for article (PubMed ID: 34471057)

  • 1. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
    Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
    Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
    Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
    Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M
    Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    Norby FL; Alonso A
    J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
    J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
    Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A
    J Comp Eff Res; 2019 Feb; 8(3):165-178. PubMed ID: 30654626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
    Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
    Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
    Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
    J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.